This is a prospective multicenter cohort study to evaluate the prognostic value of new biological markers in predicting thrombotic events after orthopedic surgery. According to the inclusion and non-inclusion criteria below, the study will include 387 major subjects who will undergo first-line total knee replacement and will receive the same standard prophylactic treatment: anticoagulation with Lovenox® (enoxaparin) 4000 IU/d subcutaneously 6 to 8 hours postoperatively and then daily for 15 days in combination with compression stockings.
Subject, male or female, aged 18 to 85 years (upper age limit classically used in the literature of PTG79-81)
First-line TKP (knee native to any prosthesis) performed to treat primary or secondary osteoarthritis.
ASA score <4 (American Society of Anesthesiologists)
No contraindication to prophylactic treatment with low molecular weight heparin (LMWH)
Subjects with a history of sepsis, tumor or trauma in the considered joint
Subject with sepsis or acute infection
Immunocompromised subject (HIV, transplant, chemotherapy, leukemia, glucocorticoids >3 months)
Subjects with severe respiratory, circulatory or cardiac pathologies involving anticoagulant treatment likely to influence the coagulolytic balance.